| Dr Forrest Smith, DO | |
|
240 Hospital Rd, Whitesburg, KY 41858-7627 | |
| (606) 633-3590 | |
| Not Available |
| Full Name | Dr Forrest Smith |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 240 Hospital Rd, Whitesburg, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982228433 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 05413 (Kentucky) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Entity Name | Southern Medical Partners, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538109962 PECOS PAC ID: 8123923679 Enrollment ID: O20031206000036 |
News Archive
American soldiers critically wounded in Iraq are being treated with a potent, experimental, blood-coagulating drug despite evidence it can cause clots in the lungs, heart and brain, leading to strokes, heart attacks and death.
Usha Kiran Tarigopula, deputy director in global health at the Bill & Melinda Gates Foundation, writes about the Foundation's partnership with the state of Bihar, India through the Ananya Alliance "aimed at reducing maternal, newborn, and child mortality by 40 percent by 2015," in this "Inpatient Optimists" blog post, which is part of a series called "Global Conversations on Newborn Health in India."
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.
› Verified 8 days ago
| Entity Name | Hyden Emergency Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497036776 PECOS PAC ID: 6103099163 Enrollment ID: O20111108000187 |
News Archive
American soldiers critically wounded in Iraq are being treated with a potent, experimental, blood-coagulating drug despite evidence it can cause clots in the lungs, heart and brain, leading to strokes, heart attacks and death.
Usha Kiran Tarigopula, deputy director in global health at the Bill & Melinda Gates Foundation, writes about the Foundation's partnership with the state of Bihar, India through the Ananya Alliance "aimed at reducing maternal, newborn, and child mortality by 40 percent by 2015," in this "Inpatient Optimists" blog post, which is part of a series called "Global Conversations on Newborn Health in India."
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Forrest Smith, DO 42 Hayes St, Whitesburg, KY 41858-7244 Ph: (859) 940-8594 | Dr Forrest Smith, DO 240 Hospital Rd, Whitesburg, KY 41858-7627 Ph: (606) 633-3590 |
News Archive
American soldiers critically wounded in Iraq are being treated with a potent, experimental, blood-coagulating drug despite evidence it can cause clots in the lungs, heart and brain, leading to strokes, heart attacks and death.
Usha Kiran Tarigopula, deputy director in global health at the Bill & Melinda Gates Foundation, writes about the Foundation's partnership with the state of Bihar, India through the Ananya Alliance "aimed at reducing maternal, newborn, and child mortality by 40 percent by 2015," in this "Inpatient Optimists" blog post, which is part of a series called "Global Conversations on Newborn Health in India."
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.
FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.
› Verified 8 days ago
Mahmood Alam, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 226 Medical Plaza Lane, Whitesburg, KY 41858 Phone: 606-633-4871 Fax: 606-633-0883 | |
April Lynn Hall-slone, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 226 Medical Plaza Ln, Whitesburg, KY 41858 Phone: 606-633-4871 Fax: 606-633-1874 | |
Kevin Matthew Gooch, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 214 Hospital Rd, Whitesburg, KY 41858 Phone: 606-633-3631 Fax: 606-633-3204 | |
William Martin Collins, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 109 E Main St, Whitesburg, KY 41858 Phone: 606-633-4488 Fax: 606-633-8383 | |
Dr. Salahadin M Gharad, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 226 Medical Plaza Ln, Suite C, Whitesburg, KY 41858 Phone: 606-633-2273 Fax: 606-633-6204 | |
Dr. Matthew Troy Breeding, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 226 Medical Plaza Ln, Whitesburg, KY 41858 Phone: 606-633-4823 Fax: 606-633-1874 | |
Abubakar H Tidal, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 214 Hospital Rd, Whitesburg, KY 41858 Phone: 606-633-3631 Fax: 606-633-6204 |